Skip to main content
  • Home
  • Dual antiplatelet therapy for acute stroke and TIA: Current best practice and emerging strategies

Dual antiplatelet therapy for acute stroke and TIA: Current best practice and emerging strategies

Topic:
  • Heart Failure
  • Prevention

Available Credit:

  • 1.00 EBAC

Course Published On:

Course Expiry Date:

Overview

In the days and weeks following a minor stroke or transient ischaemic attack (TIA), patients are at increased risk for a secondary stroke. Secondary strokes are common and are often more disabling and more likely to be fatal than the index event. Patients are at the greatest risk for a secondary stroke in the 30 days following an acute event, with an estimated 5.2% of patients experiencing a recurrent ischaemic stroke in the first 7 days after an index event. Clinical studies have demonstrated that the acute treatment of ischaemic stroke or TIA should include antiplatelet therapy within 24 hours of an index event with dual antiplatelet therapy (DAPT; aspirin + clopidogrel) recommended for 21 days after an event. While the benefit of DAPT for reducing thrombotic risk after a stroke has been established, findings from recent studies suggest that alternative agents and durations of treatment following and acute minor ischaemic stroke or TIA may further reduce the risk of secondary stroke and improve outcomes for patients. Such data also highlight the need for a personalized approach to secondary stroke prevention which takes account of individual risk factors in terms of underlying causation, health status and bleeding risk. Increased awareness among physicians of these recent developments and strategies to assess early stroke risk and use this information to guide the choice of therapy is necessary to implement these findings in clinical practice.

Disclosure

In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.

 

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

 

This programme is supported by an unrestricted educational grant from AstraZeneca. The scientific programme has not been influenced in any way by the sponsor.

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

 

This session ‘Dual antiplatelet therapy for acute stroke and TIA: Current best practice and emerging strategies’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

 

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

Instructions to Participants

There is no fee for taking part in this online learning activity.

 

Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

 

To complete the course and claim certification participants must:

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.

Learning Objectives

  • To highlight the continued high unmet need for strategies to prevent stroke or death for patients experiencing acute stroke or TIA
  • To outline the guidelines on the use of dual antiplatelet therapy for patients presenting with acute stroke or TIA
  • To examine recent evidence from clinical trials on novel strategies for improving outcomes for patients presenting with acute stroke or TIA and how these data and insights can be applied in clinical practice
Register now Log in

Module

Title

Duration

Speakers

1 Chairperson’s welcome and introduction Pierre Amarenco (Paris University, FR)
2 Secondary prevention following acute minor stroke or TIA: Understanding the ongoing risk Peter M Rothwell (University of Oxford, UK)
3 Current best practice: Evidence-based antiplatelet therapy for secondary stroke prevention Pierre Amarenco (Paris University, FR)
4 Evolving role of dual antiplatelet therapy for stroke prevention: Advancing best practice for patients at high risk Clay Johnston (The University of Texas, Austin, US)
5 Clinical decision making for the patient presenting with acute stroke Peter D Schellinger (Universitatslinikum Der Ruhr-Universitat Bochum, DE)
6 Faculty discussion: The use of anti-platelet therapy to manage patients following an acute stroke Pierre Amarenco (Paris University, FR) Peter M Rothwell (University of Oxford, UK) Clay Johnston (The University of Texas, Austin, US) Peter D Schellinger (Universitatslinikum Der Ruhr-Universitat Bochum, DE)
1.

Chairperson’s welcome and introduction

Duration:

Speakers: Pierre Amarenco (Paris University, FR)

2.

Secondary prevention following acute minor stroke or TIA: Understanding the ongoing risk

Duration:

Speakers: Peter M Rothwell (University of Oxford, UK)

3.

Current best practice: Evidence-based antiplatelet therapy for secondary stroke prevention

Duration:

Speakers: Pierre Amarenco (Paris University, FR)

4.

Evolving role of dual antiplatelet therapy for stroke prevention: Advancing best practice for patients at high risk

Duration:

Speakers: Clay Johnston (The University of Texas, Austin, US)

5.

Clinical decision making for the patient presenting with acute stroke

Duration:

Speakers: Peter D Schellinger (Universitatslinikum Der Ruhr-Universitat Bochum, DE)

Course Director

Pierre Amarenco

Paris University

Pierre Amarenco is Professor of Neurology at Paris University, France. He also serves as Chair of the Department of Neurology and Stroke Center, and also of the SOS-TIA Clinic at Bichat University Hospital in Paris.

View full profile

Speaker

Peter M Rothwell

University of Oxford

Peter M Rothwell is Founding Director, at the Wolfson Centre for Prevention of Stroke and Dementia, Action Research Professor of Neurology, at the University of Oxford, UK

View full profile

Clay Johnston

Dell Medical School

Clay Johnston is the inaugural Dean of Dell Medical School and Vice President for Medical Affairs at The University of Texas at Austin.

View full profile

Peter D Schellinger

Johannes Wesling Klinikum Minden

Peter D Schellinger is Chairman of the Department of Neurology and Neurogeriatrics at Johannes Wesling Klinikum Minden at the Universitatslinikum Der Ruhr-Universitat Bochum.

View full profile

AVAILABLE CREDIT

1.00 European Board for Accreditation in Cardiology (EBAC)

Related Courses

SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
  • 1 EBAC

Learning objectives

  • Recall the results of key trials in HFmrEF in different patients' sub-groups
  • Describe how SGLT-2 inhibitors can be used across the range of LVEF
  • Apply emerging diagnostic approaches for HFpEF and HFmrEF
  • Implement best-practice strategies across the range of LVEF
See more
Making Gains in HFpEF: An Appraisal of Where We Are Now

Learning objectives

  • Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
  • Recall current inertia rates amongst prescribers who manage heart failure
  • Adopt effective treatment strategies for HFpEF patients early in the disease course
  • Recall current guideline directed medical therapy options in HFpEF
  • Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
See more
Heart Failure Management in a Changing Paradigm
  • 1 EBAC

Learning objectives

  • Recall the utility of EF in heart failure treatment, patient selection and treatment response
  • Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
  • InIncorporate quality of life measures for assessing therapeutic efficacy in HF
  • Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
See more
The 2022 ACC Heart Failure Guidelines: What Do They Mean for Your Practice?

Learning objectives

  • Summarise the main updates to the 2022 ACC heart failure (HF) guidelines
  • Compare updates from the ACC with the 2021 ESC HF guidelines
  • Recall guideline recommendations for the initiation of foundational therapy for heart failure
  • Adopt foundational GMDT early in the disease course
  • Postulate how ejection fraction will be used in future trials and in future guidelines
  • Review existing and forthcoming trial evidence on SGLT-2 inhibitors in HFpEF
See more
HFO 2022 - Session 3.3: Live Case & Discussion
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 3.1 & 3.2: Quality of Life and Multi-disciplinary Care in HF
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 2.5 Practical Theory & Hot Topics: Advanced HF Care
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 2.3 Practical Theory & Hot Topics: HF Aetiology
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 2.2 Live Case and Discussion
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 1.4 Practical Theory & Hot Topics: Transitioning Care and Monitoring Technology
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more